Antibody Therapeutics for Life

Notices

`` Evaluation of drug mechanism and efficacy of a novel anti-angiogenic agent, TTAC-0001, using multi-modality bioimaging in a mouse breast cancer orthotopic model`` is now indexed on PubMed.
  • Written by Admin
  • Written date 2019-01-14 11:35:28
  • Inquire 1835

" Evaluation of drug mechanism and efficacy of a novel anti-angiogenic agent, TTAC-0001, using multi-modality bioimaging in a mouse breast cancer 

orthotopic model" is now indexed on PubMed.

 

 

PharmAbcine, a clinical stage immune-oncology company, today announced that " Evaluation of drug mechanism and efficacy of a novel anti-angiogenic agent, TTAC-0001, using multi-modality bioimaging in a mouse breast cancer orthotopic model " is now indexed on PubMed.

 

 

PONE-D-17-27311R2

Evaluation of drug mechanism and efficacy of a novel anti-angiogenic agent, TTAC-0001, using multi-modality bioimaging in a mouse breast cancer 

orthotopic model

 

 

Link to paper on PubMed: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5784895/#__ffn_sectitle

List





Prev ``Preclinical pharmacokinetics, interspecies scaling, and pharmacokinetics of a ...
Next PharmAbcine Announces FDA Orphan Drug Designation Granted to TTAC-0001 for Gliob...